Antihemophilic Factor, Pegylated (Mw 20000) Human Sequence Recombinant
A recombinant form of clotting Factor VIII that has been chemically modified with polyethylene glycol to extend its time in circulation, reducing the frequency of injections needed. It is used to prevent and treat bleeding episodes in people with hemophilia A.
Peso molecular
508,6000 g/mol
LogP
-3,60
TPSA
197,00 Ų
Regla de cinco de Lipinski
No cumple
Mecanismo de acción
As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.
Estructura 2D
Cite this structure
Embed this structure
SMILES
COCCNC(=O)OCC(COC(=O)NCCOC)OCCCC(=O)NCCCC[C@@H](C(=O)O)N
InChI
InChI=1S/C21H40N4O10/c1-31-12-9-24-20(29)34-14-16(15-35-21(30)25-10-13-32-2)33-11-5-7-18(26)23-8-4-3-6-17(22)19(27)28/h16-17H,3-15,22H2,1-2H3,(H,23,26)(H,24,29)(H,25,30)(H,27,28)/t17-/m0/s1
Molecular Formula
C21H40N4O10
HBD / HBA
5 / 11
Enlaces Rotables
23
Átomos Pesados
35
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
A recombinant form of clotting Factor VIII that has been chemically modified with polyethylene glycol to extend its time in circulation, reducing the frequency of injections needed. It is used to prevent and treat bleeding episodes in people with hemophilia A.
As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.
Yes, Antihemophilic Factor, Pegylated (Mw 20000) Human Sequence Recombinant is an approved drug. It has reached clinical phase 4. It is classified as a Unknown.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4594584. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 86278357. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="antihemophilic-factor-pegylated-mw-20000-human-sequence-recombinant"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/antihemophilic-factor-pegylated-mw-20000-human-sequence-recombinant/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/antihemophilic-factor-pegylated-mw-20000-human-sequence-recombinant/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/antihemophilic-factor-pegylated-mw-20000-human-sequence-recombinant/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="antihemophilic-factor-pegylated-mw-20000-human-sequence-recombinant"></drugfyi-drug>